ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1763

Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis

Robert Landewé1, Daniel H Solomon2, Gianluca Bonfanti3, Luigi Manca3, John C Woolcott4, Jasper Deuring5, Stephen Watt6, Pritha Bhadra Brown6, Rebecca Germino6, Birol Emir6 and Roger A Edwards7, 1Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 2Brigham and Women's Hospital, Boston, MA, 3Fair Dynamics Consulting, SRL, Milan, Italy, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Rotterdam, Netherlands, 6Pfizer Inc, New York, NY, 7Health Services Consulting Corporation, Boxborough, MA

Meeting: ACR Convergence 2020

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), prognostic factors, rheumatoid arthritis, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus expediting treatment optimization, improving outcomes, and reducing exposure to ineffective therapies. This exploratory study aimed to predict treatment outcomes to tofacitinib in patients with RA using hierarchical cluster analysis of baseline (BL) data, and cluster-specific regressions using BL data only vs BL data + early treatment response profiles.

Methods: This analysis included data from Phase 3 (NCT00814307; NCT00847613; NCT00856544; NCT00853385) and Phase 3b/4 (NCT02187055) randomized controlled trials (RCTs) of tofacitinib in patients with RA. Data were included from patients randomized to receive tofacitinib 5 mg twice daily (BID; monotherapy or + MTX/other csDMARDs) with ≥ 4 Clinical Disease Activity Index (CDAI) data points during 6 months of treatment and moderate/high BL CDAI severity; patients who discontinued the RCTs were assessed case-by-case for inclusion. A bottom-up hierarchical cluster analysis (using BL data) was conducted to improve prediction of tofacitinib response by identifying patient subgroups for cluster-specific regression models (using BL data ± early response profiles). The primary outcome was prediction of CDAI responder status at Month (M)6, using BL, M1, and M3 data, defined as achievement of minimum clinically important difference (MCID; CDAI change of 11/6/2 for patients with high/moderate/low BL CDAI severity); achievement of low disease activity (2.8< CDAI ≤ 10) or remission (CDAI ≤ 2.8) (ie treat-to-target approach for response) was also assessed. For cluster-specific regressions, patients of each cluster were randomized to a training (model development) or testing (model evaluation) dataset. The algorithm for outcome prediction consisted of all fixed BL demographics (eg age) ± time-lagged (M1 and M3) covariates (eg CDAI).

Results: Data from 1,617 patients with RA using tofacitinib 5 mg BID were included. Hierarchical cluster analysis using BL data had 6 clustering variables (tofacitinib monotherapy/combination therapy, prior corticosteroid use, smoking status, BL CDAI, BL HAQ-DI, BL pain discordance) and 5 unique clusters (ie subgroups; Figure 1). The training dataset (1,182 patients; 73.1%) was used to develop cluster-specific regressions which were then assessed in a testing dataset (435 patients; 26.9%). When regression models were used to predict outcome in the testing dataset using only BL data, prediction of MCID-defined CDAI responder status at M6 was correct for 81.1% of patients (Figure 2). Using BL + time-lagged covariates, prediction of MCID-defined CDAI responder status was correct for 84.4% of patients (Figure 2).

Conclusion: This hybrid of clustering and cluster-specific regressions, taking into account early treatment response profiles, is an interesting approach worthy of further exploration for predicting and improving long-term tofacitinib treatment outcomes in patients with RA.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Emma Deeks, CMC Connect, and funded by Pfizer Inc.


Disclosure: R. Landewé, AbbVie, 2, 5, 8, AstraZeneca, 5, Bristol-Myers Squibb, 5, 8, Eli Lilly, 5, Galapagos, 5, Novartis, 5, Pfizer Inc, 2, 5, 8, UCB, 2, 5, 8, GlaxoSmithKline, 5, Janssen, 2, 5, 8, Merck, 5, 8, Rheumatology Consultancy BV, 1, Ablynx, 5, Amgen, 2, 5, 8, Celgene, 5, Gilead, 5, Novo Nordisk, 5, Roche, 2, 5, 8, Schering, 2, 5, 8, TiGenix, 5; D. Solomon, AbbVie, 2, Amgen, 1, Genentech, 1, Janssen, 1, Corrona, 1; G. Bonfanti, Fair Dynamics Consulting, 1, 3, Health Services Consulting Corporation, 5; L. Manca, Fair Dynamics Consulting, 3, Health Services Consulting Corporation, 5; J. Woolcott, Pfizer Inc, 1, 3; J. Deuring, Pfizer Inc, 1, 3; S. Watt, Pfizer Inc, 1, 3; P. Bhadra Brown, Pfizer Inc, 1, 3; R. Germino, Pfizer Inc, 1, 3; B. Emir, Pfizer Inc, 1, 3; R. Edwards, Health Services Consulting Corporation, 1, Pfizer Inc, 5.

To cite this abstract in AMA style:

Landewé R, Solomon D, Bonfanti G, Manca L, Woolcott J, Deuring J, Watt S, Bhadra Brown P, Germino R, Emir B, Edwards R. Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/blending-hierarchical-cluster-analysis-and-cluster-specific-regressions-to-predict-clinical-outcome-to-tofacitinib-treatment-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blending-hierarchical-cluster-analysis-and-cluster-specific-regressions-to-predict-clinical-outcome-to-tofacitinib-treatment-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology